Plants are quietly borrowing tricks from bacteria, repurposing foreign genes to build complex molecules that look a lot like ...

Traws Pharma, Inc. (TRAW) has disclosed a new risk, in the Corporate Activity and Growth category. The integration of Onconova and Trawsfynydd poses a significant risk to Traws Pharma, Inc.’s future ...

Quick Read Eli Lilly (LLY) and Nvidia (NVDA) will invest up to $1B over five years in an AI drug discovery lab. AI could ...

By the end of 2026, the outlines of the next-generation pharmaceutical company will already be taking shape. Organizations that reimagine discovery, reinvent operations, and redesign patient ...

Patient access to innovative new therapies requires us to reimagine the supply chain and how it integrates advanced technologies.

Industry anxiety over growth and pricing pressures leads to cautious investment, resulting in slower growth and a ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408 TEV- ...

We’ve seen the first AI-generated commercials, songs and even social media influencers outside of healthcare. Will pharma be ...

My initial rating of Abbott Laboratories is a buy, agreeing with today's Wall Street consensus. The future growth indicators, diversified portfolio across many clinical segments, and leading roles in ...

Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

Pharma marketers frequently cite the need to craft marketing that’s rooted in empathy. For Katie Williams, chief marketing officer (CMO) at GSK’s consumer health spinoff Haleon, empathy manifests as ...